Avanir Pharmaceuticals Pays More than $108 Million to Settle Kickback Violations
Michael Volkov warns that pharmaceutical and medical device firms face extraordinary risks of enforcement under the False Claims Act, significantly outweighing their FCPA or anti-corruption risks.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.